Precigen, Inc. (NASDAQ:PGEN) shares are trading higher on Monday after the company completed the rolling submission for a biologics license application to the FDA for PRGN-2012 (zopapogene imadenovec) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback